rosiglitazone
NN1998-1682
Phase 3 small_molecule terminated
Quick answer
rosiglitazone for Diabetes is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Diabetes
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated